Literature DB >> 31248782

tRNA Deregulation and Its Consequences in Cancer.

Mafalda Santos1, Ana Fidalgo2, A Sofia Varanda1, Carla Oliveira3, Manuel A S Santos4.   

Abstract

The expression of transfer RNAs (tRNAs) is deregulated in cancer cells but the mechanisms and functional meaning of such deregulation are poorly understood. The proteome of cancer cells is not fully encoded by their transcriptome, however, the contribution of mRNA translation to such diversity remains to be elucidated. We review data supporting the hypothesis that tRNA expression deregulation and translational error rate is an important contributor to proteome diversity and cell population heterogeneity, genome instability, and drug resistance in tumors. This hypothesis is aligned with recent data in various model organisms, showing unanticipated adaptive roles of translational errors (adaptive mistranslation), expression control of specific gene subsets by tRNAs, and proteome diversification by elevation of translational error rates in tumors.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer; codon usage; drug resistance; protein synthesis errors; tRNAs

Mesh:

Substances:

Year:  2019        PMID: 31248782     DOI: 10.1016/j.molmed.2019.05.011

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  23 in total

Review 1.  Small non-coding RNAs in human cancer: function, clinical utility, and characterization.

Authors:  Zhao Zhang; Jian Zhang; Lixia Diao; Leng Han
Journal:  Oncogene       Date:  2021-01-15       Impact factor: 9.867

2.  LOTTE-seq (Long hairpin oligonucleotide based tRNA high-throughput sequencing): specific selection of tRNAs with 3'-CCA end for high-throughput sequencing.

Authors:  Lieselotte Erber; Anne Hoffmann; Jörg Fallmann; Heike Betat; Peter F Stadler; Mario Mörl
Journal:  RNA Biol       Date:  2019-09-16       Impact factor: 4.652

3.  Dynamic changes in tRNA modifications and abundance during T cell activation.

Authors:  Roni Rak; Michal Polonsky; Inbal Eizenberg-Magar; Yufeng Mo; Yuriko Sakaguchi; Orel Mizrahi; Aharon Nachshon; Shlomit Reich-Zeliger; Noam Stern-Ginossar; Orna Dahan; Tsutomu Suzuki; Nir Friedman; Yitzhak Pilpel
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-19       Impact factor: 11.205

Review 4.  Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes.

Authors:  Nayiri M Kaissarian; Douglas Meyer; Chava Kimchi-Sarfaty
Journal:  J Natl Cancer Inst       Date:  2022-08-08       Impact factor: 11.816

Review 5.  The expanding world of tRNA modifications and their disease relevance.

Authors:  Tsutomu Suzuki
Journal:  Nat Rev Mol Cell Biol       Date:  2021-03-03       Impact factor: 94.444

Review 6.  RNA in cancer.

Authors:  Gregory J Goodall; Vihandha O Wickramasinghe
Journal:  Nat Rev Cancer       Date:  2020-10-20       Impact factor: 60.716

7.  DALRD3 encodes a protein mutated in epileptic encephalopathy that targets arginine tRNAs for 3-methylcytosine modification.

Authors:  Jenna M Lentini; Hessa S Alsaif; Eissa Faqeih; Fowzan S Alkuraya; Dragony Fu
Journal:  Nat Commun       Date:  2020-05-19       Impact factor: 14.919

8.  The p53 family reaches the final frontier: the variegated regulation of the dark matter of the genome by the p53 family in cancer.

Authors:  Marco Napoli; Elsa R Flores
Journal:  RNA Biol       Date:  2020-01-07       Impact factor: 4.652

Review 9.  Translational Regulation of Cancer Metastasis.

Authors:  Douglas S Micalizzi; Richard Y Ebright; Daniel A Haber; Shyamala Maheswaran
Journal:  Cancer Res       Date:  2021-01-21       Impact factor: 13.312

10.  METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation.

Authors:  Esteban A Orellana; Qi Liu; Eliza Yankova; Mehdi Pirouz; Etienne De Braekeleer; Wencai Zhang; Jihoon Lim; Demetrios Aspris; Erdem Sendinc; Dimitrios A Garyfallos; Muxin Gu; Raja Ali; Alejandro Gutierrez; Sigitas Mikutis; Gonçalo J L Bernardes; Eric S Fischer; Allan Bradley; George S Vassiliou; Frank J Slack; Konstantinos Tzelepis; Richard I Gregory
Journal:  Mol Cell       Date:  2021-08-04       Impact factor: 19.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.